Table 1: Characteristics and outcome of patients in the series. Column “All patients” includes the whole series of patients with normal platelets or thrombocytosis. test between the group with normal platelet count and the group with thrombocytosis is shown. Wherever there are more than two categories, the grouping of the comparison is mentioned in the same column. Her-2 was defined as positive if 3+ by IHC or amplified by FISH and negative if 1+ by IHC or 2+ by IHC and FISH not amplified or not performed.

All patientsnormalthrombocytosis

Number (%)165 (100)135 (81.8)30 (18.2)
Age at diagnosis of metastatic disease
 Median (range)62 (31–92)62 (31–92)66 (44–85)
 >65 years 70 (42.4)54 (40)16 (53.3)
 ≤65  years95 (57.6)81 (60)14 (46.7)
ER/PRPositive versus negative  
 Positive (either or both)126 (76.4)102 (75.5)24 (80)
 Negative (both)37 (22.4)31 (23)6 (20)
 Unknown2 (1.2)2 (1.5)0
Her-2Positive versus negative 
 Positive35 (21.2)27 (20)8 (26.7)
 Negative107 (64.9)90 (66.7)17 (56.7)
 Unknown or ambiguous23 (13.9)18 (13.3)5 (16.6)
GradeIII versus I and II 
 I10 (6.1)8 (6)2 (6.7)
 II66 (40)55 (40.7)11 (36.6)
 III67 (40.6)52 (38.5)15 (50)
 Unknown22 (13.3)20 (14.8)2 (6.7)
Metastatic at diagnosis
 Yes67 (40.6)46 (34.1)21 (70)
 No98 (59.4)89 (65.9)9 (30)
Sites of metastasesBone only versus other 
  
 Bone41 (24.9)34 (25.2)7 (23.3)
 Soft tissue21 (12.7)20 (14.8)1 (3.3)
 Parenchymal38 (23)34 (25.2)4 (13.4)
 Multiple sites65 (39.4)47 (34.8)18 (60)
1st metastatic treatment
 None or hormonotherapy74 (44.8)63 (46.7)11 (36.7)
 Chemotherapy91 (55.2)72 (53.3)19 (63.3)
Adjuvant treatment
 None or hormonotherapy52 (53.1)47 (52.8)5 (55.6)
 Chemotherapy46 (46.9)42 (47.2)4 (44.4)